GlassScriptPhysician profile
David Andrew Steiner
NPI 1972508802
$8,743.04
in general payments reported to CMS, 2019-2025
36 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $685 · 2021: $1,140 · 2022: $1,395 · 2023: $1,394 · 2024: $1,508 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,541 · Education: $99.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,541.34 |
| Education | $99.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.77 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $855.54 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Neurocrine Biosciences, INC. | $855.39 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $687.32 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $647.03 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $631.11 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Acadia Pharmaceuticals INC | $525.44 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $404.54 | 2019-2025 | Rexulti |
| Alkermes, INC. | $396.57 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $324.19 | 2019-2020 | |
| Axsome Therapeutics, INC. | $285.32 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $204.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $197.97 | 2020-2023 | Belsomra |
| Eisai INC. | $181.40 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $159.84 | 2024-2025 | Cobenfy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $159.09 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $120.68 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $108.22 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $100.76 | 2019-2022 | |
| Noven Therapeutics, LLC | $96.61 | 2024-2025 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $91.28 | 2019-2021 | |
| Corium, LLC | $74.36 | 2023-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $71.47 | 2019-2025 | Hetlioz, Fanapt |
| Adlon Therapeutics L.P. | $66.28 | 2020-2021 | |
| Tris Pharma INC | $64.37 | 2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $57.43 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $51.56 | 2025 | Jornay Pm |
| Sumitomo Pharma America, INC. | $47.66 | 2024 | Aptiom |
| Supernus Pharmaceuticals, INC. | $47.02 | 2022-2023 | Qelbree |
| Lilly USA, LLC | $38.67 | 2023-2025 | Amyvid, Kisunla |
| Sunovion Pharmaceuticals INC. | $33.42 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $22.54 | 2023 | Trudhesa |
| Vertical Pharmaceuticals, LLC | $19.45 | 2019 | |
| Neuronetics, INC. | $15.33 | 2019 | |
| Bioxcel Therapeutics, INC. | $13.89 | 2023 | Igalmi |
| Alfasigma USA, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.